Replies to post #3536 on CardioVascular BioTherapeutics (fka CVBT)

[walhall]

You are incorrect, Dentons made it extremely clear that there are no assets of value at Venturis and thus the patents have no value. Let me quote from Barry Cannaday's sworn statement to the U.S. Federal Court: "Upon investigation as to Venturis ability to pay legal fees in accordance with its agreement, it has become evident that there are currently no assets or revenue streams from which payments can be made."

If you are correct and any of Venturis's assets have any meaningful value and therefore could have been used to pay Dentons, contrary to the sworn statement of Mr. Cannaday, he will have made a false statement to the court and would be subject to disbarment.

So let's summarize: A partner at one of the largest law firms in the country has stated to the U.S. Federal Court that the assets of Venturis Therapeutics are worthless. In contrast, an anonymous supporter of the company (who does not identify themself as Mr. Cannaday has) is saying that Mr. Cannaday's statement is false, without offering any evidence.